Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatments for type 2 diabetes and obesity and are being explored for potential use in substance use disorders.
- Randomized evidence is emerging that suggests GLP-1 RAs may have effects in alcohol use disorder.
- Evidence for the use of GLP-1 RAs in treating opioid, nicotine, cocaine, cannabis, and stimulant use disorders is currently mixed.
- Many studies exploring GLP-1 RAs for substance use disorders are observational or investigational in nature.
Simplified